A commercial driver who uses cannabis under a state medical program may still face a verified positive drug test under federal transportation rules, even if the substance was obtained legally within that state.
The issue has become more significant as federal officials begin changing cannabis’ classification under the CSA. The Transport Department has made clear that a shift toward Schedule 3 does not, by itself, permit marijuana use by workers in safety-sensitive transport roles.
Last December, President Donald Trump directed the Justice Department to accelerate proceedings that could shift cannabis to Schedule 3. DOT said at the time that its testing requirements remained unchanged.
In April, the DEA placed certain FDA-approved marijuana products and marijuana covered by state medical programs in Schedule 3. Meanwhile, a broader proceeding concerning marijuana’s overall federal classification continued, with hearings held during late June and July.
Controlled substances placed in Schedule 3 remain subject to federal restrictions. A change in scheduling doesn’t automatically make state-approved medical cannabis permissible under federal rules or eliminate workplace drug-testing requirements.
DOT oversees drug-testing requirements affecting millions of workers in aviation, trucking, rail, pipelines, transit, and other transportation sectors. The department has pointed to federal legislation enacted in 1991 as authority for testing controlled substances that present transportation safety concerns when used.
The technical framework presents additional questions. DOT testing operates alongside federal workplace testing guidelines administered by the DHHS and laboratories certified under those requirements. Marijuana remains part of the federal testing panel, although some parts of the framework refer specifically to substances in Schedules 1 and 2. DOT and HHS have been examining how broader rescheduling could affect those requirements.
For medical-review officers, the current position is clearer. A worker cannot generally overturn a confirmed cannabis result simply by producing their state medical-cannabis card, doctor’s recommendation, or dispensary documentation. DOT guidelines say such state authorization does not constitute a federally recognized prescription under the CSA.
That means a driver who legally purchased cannabis through a licensed state dispensary could still have a positive DOT result verified rather than dismissed.
Commercial drivers also face separate requirements administered by the FMCSA. Existing FMCSA guidelines have treated marijuana use as incompatible with federal qualification standards, although that guidance was developed when cannabis remained in Schedule 1.
Federal regulations distinguish Schedule 1 substances from certain drugs in Schedules 2 through 5, creating a question about how the rules will apply if marijuana is ultimately classified more broadly in Schedule 3. FMCSA may therefore need to clarify how its medical-qualification standards interact with the changing federal schedule.
For now, employers should continue following existing DOT testing requirements. State legalization does not override federal transportation rules, and the April DEA action does not establish that commercial drivers may use medical cannabis.
Transportation companies should monitor developments from DEA, DOT, HHS, and FMCSA rather than relying solely on changes to cannabis’ federal classification. The scheduling process may alter federal policy, but it does not by itself determine what cannabis use means for employees operating within safety-sensitive transport roles.
For now, cannabis industry operators like Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) will continue monitoring the federal drug regulatory landscape as it evolves in terms of what is or isn’t permitted for employees.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is powered by IBN
